bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

Core Insights - bioAffinity Technologies, Inc. has presented a new scientific poster demonstrating its innovative diagnostic approach for identifying antibody drug receptors in sputum, which is significant for personalized treatment decisions in asthma and COPD patients [1][2] Company Overview - bioAffinity Technologies focuses on noninvasive diagnostics and early cancer detection, with its first product, CyPath® Lung, designed to improve early detection of lung cancer [5] - The company utilizes a proprietary flow cytometry platform with automated AI analysis to develop tests that match asthma and COPD patients with appropriate biologic therapies [2][3] Product Details - CyPath® Lung is a noninvasive test that has shown 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small pulmonary nodules [4] - The test incorporates a fluorescent porphyrin that preferentially targets cancer and cancer-related cells, enhancing its diagnostic capabilities [4] Market Context - Asthma and COPD affect approximately 650 million individuals globally, highlighting the need for effective diagnostic and treatment solutions [3] - The company aims to assist physicians in matching patients with effective therapies and monitoring their conditions over time to improve healthcare outcomes and reduce costs [2][3]